ValuEngine cut shares of Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) from a hold rating to a sell rating in a report issued on Wednesday.

Separately, Roth Capital reaffirmed a buy rating on shares of Matinas BioPharma Holdings in a research report on Monday, July 10th.

Matinas BioPharma Holdings (NYSEMKT:MTNB) opened at 1.25 on Wednesday. The stock’s market cap is $114.97 million. Matinas BioPharma Holdings has a 52-week low of $1.01 and a 52-week high of $3.99. The stock has a 50 day moving average price of $1.29 and a 200 day moving average price of $2.28.

TRADEMARK VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Downgraded to Sell at ValuEngine” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with's FREE daily email newsletter.